top of page

Search Results

Search this site

658 results found with an empty search

  • US Radiologist Compensation Reaches $609,684 in Doximity’s 2026 Report

    Average annual compensation for US radiologists reached $609,684 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US radiologists recorded average annual compensation of $609,684, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides radiologists with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $609,684 for radiologists in its 2026 Physician Compensation Report. For radiologists, the figure provides a useful national reference point within a specialty central to the diagnosis, monitoring and management of patients across virtually every area of medicine. The national average should not be interpreted as the compensation every radiologist will receive. Individual earnings can vary according to geography, experience, subspecialty expertise, workload, call responsibilities, practice setting and employment structure. Radiologist compensation reaches $609,684 The $609,684 average establishes a current national compensation benchmark for US radiologists. Radiology encompasses the interpretation of imaging across modalities including X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and other diagnostic technologies. Individual radiologists may also develop specialist expertise in areas such as neuroradiology, musculoskeletal imaging, breast imaging, cardiothoracic imaging, abdominal imaging or pediatric radiology. These different practice profiles can result in substantially different workloads and employment arrangements. For radiologists reviewing their current compensation or considering a new opportunity, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences radiologist compensation? Radiology is heavily influenced by imaging volume, case complexity, subspecialty expertise and working arrangements. The number and type of studies interpreted can have a significant bearing on a radiologist's workload. Emergency and overnight coverage can also be an important component of some roles, particularly where practices provide continuous imaging services to hospitals and emergency departments. Practice setting can further influence compensation. Radiologists may work within private radiology groups, hospitals, academic medical centres, health systems or remote and teleradiology services, each potentially using different compensation and productivity structures. Experience, geography, call commitments, leadership responsibilities and academic or teaching duties may also affect individual compensation. These factors mean the $609,684 national average should be treated as a benchmark rather than an expected salary for every radiologist. What the latest figure means for radiologists For US radiologists, $609,684 provides a contemporary national reference point when benchmarking current compensation or assessing a prospective position. When reviewing an opportunity, radiologists should consider headline compensation alongside expected imaging volumes, modality and subspecialty mix, call requirements, working hours and productivity expectations. Working arrangements are particularly important within radiology. The expansion of remote image interpretation and teleradiology means physicians may encounter substantially different schedules and employment models even when performing similar diagnostic work. The latest Doximity figure therefore provides radiologists with a useful starting point for assessing compensation while recognising that individual earnings can differ substantially according to the structure, workload and requirements of a particular practice. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual radiologist’s compensation may differ according to geography, experience, subspecialty, imaging workload, call responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Radiation Oncologist Compensation Reaches $613,837 in Doximity’s 2026 Report

    Average annual compensation for US radiation oncologists reached $613,837 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US radiation oncologists recorded average annual compensation of $613,837, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides radiation oncologists with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $613,837 for radiation oncologists in its 2026 Physician Compensation Report. For radiation oncologists, the figure provides a useful national reference point within a specialty combining cancer care, treatment planning and the delivery of highly specialised radiation therapies. The national average should not be interpreted as the compensation every radiation oncologist will receive. Individual earnings can vary according to geography, experience, patient volume, clinical responsibilities, practice setting and employment structure. Radiation oncologist compensation reaches $613,837 The $613,837 average establishes a current national compensation benchmark for US radiation oncologists. Radiation oncology involves the assessment and management of patients receiving radiation therapy as part of their cancer treatment. Physicians work across the treatment pathway, from initial consultation and treatment planning through to therapy supervision, response assessment and follow-up care. Clinical practice can encompass multiple cancer types and treatment techniques, including external beam radiation therapy, stereotactic treatments and brachytherapy, depending on the physician's expertise and treatment centre. For radiation oncologists reviewing their current compensation or considering a new position, the Doximity figure provides a useful specialty-specific reference against which an individual package can be assessed. What influences radiation oncologist compensation? Radiation oncology is a technology-intensive specialty requiring close integration between physicians, medical physicists, dosimetrists, radiation therapists and wider multidisciplinary cancer teams. Individual compensation can be influenced by patient volume, treatment complexity, experience, geographic market and practice setting. The type of cancer centre can also be relevant. Radiation oncologists may work within academic medical centres, hospital systems, dedicated cancer centres or specialist practices, with different organisations using different compensation and productivity arrangements. Clinical leadership, research, teaching and administrative responsibilities may further influence an individual physician's role and compensation. These factors mean the $613,837 national average should be treated as a benchmark rather than an expected salary for every radiation oncologist. What the latest figure means for radiation oncologists For US radiation oncologists, $613,837 provides a contemporary national reference point when benchmarking existing compensation or evaluating a prospective position. When reviewing an employment opportunity, physicians should consider compensation alongside patient volumes, treatment responsibilities, available radiation technology, working hours, clinical support and productivity expectations. The clinical environment is particularly relevant in radiation oncology. Access to specialist equipment, multidisciplinary cancer services and appropriate technical and clinical support can materially affect the scope and demands of an individual role. The latest Doximity figure therefore provides radiation oncologists with a useful starting point for assessing compensation while recognising that an individual package needs to be considered alongside the specific clinical, organisational and contractual characteristics of the position. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual radiation oncologist’s compensation may differ according to geography, experience, patient volume, clinical responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Plastic Surgeon Compensation Reaches $625,757 in Doximity’s 2026 Report

    Average annual compensation for US plastic surgeons reached $625,757 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US plastic surgeons recorded average annual compensation of $625,757, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides plastic surgeons with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $625,757 for plastic surgeons in its 2026 Physician Compensation Report. For plastic surgeons, the figure provides a useful national reference point across a specialty that encompasses reconstructive and aesthetic procedures and can involve substantially different clinical and practice models. The national average should not be interpreted as the compensation every plastic surgeon will receive. Individual earnings can vary considerably according to geography, experience, subspecialty focus, procedure mix, practice setting and employment structure. Plastic surgeon compensation reaches $625,757 The $625,757 average establishes a current national compensation benchmark for US plastic surgeons. Plastic surgery encompasses a broad range of procedures, including reconstructive surgery following trauma, cancer or congenital conditions, as well as aesthetic surgery. Individual surgeons may also specialise in areas such as hand surgery, microsurgery, craniofacial surgery or breast reconstruction. As a result, the clinical and financial profile of one plastic surgery practice can differ considerably from another. For plastic surgeons reviewing their current compensation or considering a new opportunity, the Doximity figure provides a useful specialty-specific reference against which an individual compensation package can be assessed. What influences plastic surgeon compensation? Plastic surgery is a highly procedural specialty, meaning procedure volume, case mix and subspecialty focus can all be important when evaluating individual compensation. Practice model is particularly relevant. Plastic surgeons may work within hospitals, health systems, academic medical centres, specialist groups or independent practices, and the way physicians are compensated can vary substantially between these settings. The balance between reconstructive and aesthetic work can also affect the financial structure of a practice. Reconstructive procedures may be reimbursed through insurers or healthcare systems, while some aesthetic procedures can operate through different payment arrangements. Geography, experience, referral patterns, surgical workload and additional leadership or academic responsibilities may further influence individual compensation. These factors mean the $625,757 national average should be treated as a benchmark rather than an expected salary for every plastic surgeon. What the latest figure means for plastic surgeons For US plastic surgeons, $625,757 provides a contemporary national reference point when benchmarking current compensation or evaluating a prospective position. When reviewing an opportunity, plastic surgeons should consider the headline compensation alongside procedure mix, expected surgical volume, working hours, call commitments, productivity requirements and the structure of the practice. The distinction between different plastic surgery practice models is also important. Two surgeons working within the same specialty may have very different revenue and compensation structures depending on their balance of reconstructive and aesthetic work and whether they are employed or operate within an independent practice. The latest Doximity figure therefore provides plastic surgeons with a useful starting point for evaluating compensation while recognising that individual earnings can differ significantly according to the nature and structure of their practice. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual plastic surgeon’s compensation may differ according to geography, experience, procedural activity, subspecialty, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Pediatric Surgeon Compensation Reaches $627,126 in Doximity’s 2026 Report

    Average annual compensation for US pediatric general surgeons reached $627,126 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US pediatric general surgeons recorded average annual compensation of $627,126, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides pediatric surgeons with a specialty-specific benchmark when evaluating their compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $627,126 for Pediatric (General) Surgery in its 2026 Physician Compensation Report. For pediatric surgeons, the figure provides a useful national reference point within a highly specialised surgical field focused on the operative care of infants, children and adolescents. The national average should not be interpreted as the compensation every pediatric surgeon will receive. Individual earnings can vary according to geography, experience, surgical workload, case complexity, call responsibilities, practice setting and employment structure. Pediatric surgeon compensation reaches $627,126 The $627,126 average establishes a current national compensation benchmark for US pediatric general surgeons. Pediatric surgery encompasses the surgical management of a broad range of congenital and acquired conditions affecting children. Depending on their practice, pediatric surgeons may undertake neonatal surgery, gastrointestinal procedures, oncologic surgery, thoracic procedures, trauma care and other complex operations. The breadth and complexity of this work means individual practice profiles and workloads can differ substantially. For pediatric surgeons reviewing an existing compensation package or considering a new position, the Doximity figure provides a national specialty benchmark against which an individual offer can be assessed. What influences pediatric surgeon compensation? Pediatric general surgery combines highly specialised surgical expertise with the management of a comparatively distinct patient population, and individual compensation can be influenced by case mix, surgical volume and complexity. Call responsibilities can also be an important consideration. Pediatric surgeons working in tertiary children's hospitals and trauma centres may provide emergency surgical coverage alongside scheduled operative and outpatient activity. Geography, experience and employment structure can further influence compensation. Pediatric surgeons may work within children's hospitals, academic medical centres, health systems and specialist surgical groups, with different organisations using different salary, productivity and incentive arrangements. Academic, teaching, research and leadership responsibilities may also form part of an individual physician's role. These factors mean the $627,126 national average should be treated as a benchmark rather than an expected salary for every pediatric surgeon. What the latest figure means for pediatric surgeons For US pediatric surgeons, $627,126 provides a contemporary national reference point when benchmarking current compensation or assessing a prospective position. When considering an employment opportunity, pediatric surgeons should evaluate compensation alongside surgical volume, case complexity, call frequency, working hours, academic responsibilities and productivity expectations. The clinical environment is also important. A position within a major tertiary children's hospital may carry substantially different responsibilities from a role within another practice setting, even where both positions fall under pediatric general surgery. The latest Doximity figure therefore provides pediatric surgeons with a useful starting point for evaluating compensation while recognising that individual packages need to be assessed against the specific clinical and contractual responsibilities of the role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual pediatric surgeon’s compensation may differ according to geography, experience, surgical activity, case complexity, call responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Interventional Radiologist Compensation Reaches $634,658 in Doximity’s 2026 Report

    Average annual compensation for US interventional radiologists reached $634,658 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US interventional radiologists recorded average annual compensation of $634,658, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides interventional radiologists with a specialty-specific benchmark when evaluating compensation, employment opportunities and the financial expectations associated with their practice. Key findings Doximity reports average annual compensation of $634,658 for interventional radiologists in its 2026 Physician Compensation Report. For interventional radiologists, the figure provides a useful national reference point within a specialty combining diagnostic imaging expertise with minimally invasive image-guided procedures. The national average should not be interpreted as the compensation every interventional radiologist will receive. Individual earnings can vary according to geography, experience, procedural workload, call responsibilities, practice setting and employment structure. Interventional radiologist compensation reaches $634,658 The $634,658 average establishes a current national compensation benchmark for US interventional radiologists. Interventional radiology encompasses a broad range of image-guided procedures used to diagnose and treat disease. Depending on their clinical practice, interventional radiologists may perform vascular interventions, embolisation, biopsies, drainage procedures, ablation and other minimally invasive treatments. This combination of advanced imaging expertise and procedural medicine means individual practice profiles can vary considerably. For interventional radiologists reviewing their current compensation or considering a new position, the Doximity figure provides a useful reference against which an individual package can be assessed. What influences interventional radiologist compensation? Interventional radiology is a highly procedural specialty, meaning procedure volume, complexity and case mix can be important considerations when evaluating compensation. An individual physician's workload may vary according to the balance between interventional procedures and diagnostic radiology, the types of procedures performed and the patient population served. Call responsibilities can also be significant. Interventional radiologists may provide urgent or emergency procedures outside normal working hours, particularly within hospital-based practices and trauma services. Experience, geography and employment model can further influence compensation. Physicians working within hospitals, academic centres, radiology groups or other practice structures may have different base compensation, productivity incentives and contractual arrangements. These factors mean the $634,658 national average should be treated as a benchmark rather than an expected salary for every interventional radiologist. What the latest figure means for interventional radiologists For US interventional radiologists, $634,658 provides a contemporary national reference point when benchmarking existing compensation or assessing a prospective role. When evaluating an employment opportunity, physicians should consider the headline compensation alongside procedural expectations, diagnostic responsibilities, call frequency, working hours and productivity requirements. The precise nature of the practice is particularly relevant in interventional radiology. Two positions carrying the same specialty title may involve substantially different procedure volumes, case complexity, diagnostic workloads and on-call commitments. The latest Doximity figure therefore provides interventional radiologists with a useful starting point for assessing compensation while recognising that individual packages need to be evaluated against the responsibilities and structure of the specific role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual interventional radiologist’s compensation may differ according to geography, experience, procedural activity, call responsibilities, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Orthopaedic Surgeon Compensation Reaches $696,852 in Doximity’s 2026 Report

    Average annual compensation for US orthopaedic surgeons reached $696,852 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in the specialty. US orthopaedic surgeons recorded average annual compensation of $696,852, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides orthopaedic surgeons with a current specialty-specific benchmark when evaluating their compensation, employment arrangements and earning potential. Key findings Doximity reports average annual compensation of $696,852 for orthopaedic surgeons in its 2026 Physician Compensation Report. For orthopaedic surgeons, the figure provides a useful national reference point when assessing compensation within a specialty encompassing surgical and procedural treatment across a broad range of musculoskeletal conditions. The national average should not be interpreted as the compensation every orthopaedic surgeon should expect. Individual earnings can vary according to geography, experience, subspecialty, surgical workload, call responsibilities, practice setting and compensation structure. Orthopaedic surgeon compensation reaches $696,852 The $696,852 average establishes a new national compensation benchmark for US orthopaedic surgeons. Orthopaedic practice can encompass a wide range of clinical areas, including joint replacement, sports medicine, trauma, spine, hand and upper-extremity surgery, foot and ankle surgery and other musculoskeletal procedures. The composition of an individual surgeon’s practice can therefore have an important bearing on workload and compensation. For orthopaedic surgeons reviewing an existing employment agreement or considering a new opportunity, the Doximity figure provides a useful reference against which an individual compensation package can be assessed. However, headline compensation should always be considered alongside the clinical and contractual requirements attached to the role. What influences orthopaedic surgeon compensation? Orthopaedic surgery is a procedure-intensive specialty, and individual compensation can be influenced by surgical volume, case mix and subspecialty focus. An orthopaedic surgeon specialising in joint replacement may have a substantially different practice profile from a colleague working predominantly in trauma, sports medicine or hand surgery. Experience, productivity arrangements, geographic market and call commitments can also affect compensation. Practice setting is another important consideration. Compensation structures can differ between hospital-employed physicians, academic medical centres, single-specialty groups and other practice models. Productivity incentives, leadership responsibilities and contractual arrangements may further influence total annual compensation, meaning the national average is best used as a benchmark rather than an expected salary for every orthopaedic surgeon. What the latest figure means for orthopaedic surgeons For US orthopaedic surgeons, $696,852 provides a contemporary national reference point when benchmarking current compensation or evaluating a prospective role. When reviewing an offer, surgeons should consider how their compensation compares with the Doximity benchmark while also examining surgical volume expectations, call commitments, productivity targets, working hours and the overall structure of the package. Subspecialty and location can also be important. An individual orthopaedic surgeon’s market value may differ considerably from the national average depending on their expertise and the demand for their services within a particular geographic market. The latest Doximity figure therefore gives orthopaedic surgeons a useful starting point for assessing compensation while recognising that $696,852 represents an average across the specialty rather than an expected figure for every individual physician. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual orthopaedic surgeon’s compensation may differ according to geography, experience, working arrangements, subspecialty, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Thoracic Surgeon Compensation Reaches $749,707 in Doximity’s 2026 Report

    Average annual compensation for US thoracic surgeons reached $749,707 in Doximity’s 2026 Physician Compensation Report, providing a new national benchmark for physicians working in the specialty. US thoracic surgeons recorded average annual compensation of $749,707, according to Doximity’s 2026 Physician Compensation Report. The latest figure provides thoracic surgeons with an updated specialty-specific benchmark when evaluating their own compensation, employment arrangements and earning potential. Key findings Doximity reports average annual compensation of $749,707 for thoracic surgeons in its 2026 Physician Compensation Report. For physicians working in thoracic surgery, the figure provides a useful national reference point for assessing compensation within a specialty characterised by complex surgical care and significant procedural responsibilities. The national average should not, however, be interpreted as the amount every thoracic surgeon will earn. Individual compensation can vary considerably depending on factors such as geography, experience, workload, subspecialty focus, call responsibilities, practice setting and employment structure. Thoracic surgeon compensation reaches $749,707 The $749,707 average establishes an updated compensation benchmark for US thoracic surgeons. Thoracic surgery encompasses the surgical management of diseases affecting organs within the chest, with physicians potentially treating conditions involving the lungs, oesophagus, mediastinum and other thoracic structures. Individual practices can therefore differ substantially according to clinical focus and case mix. For thoracic surgeons reviewing their current remuneration or considering a new position, the Doximity figure offers a national specialty benchmark against which an individual compensation package can be considered. It remains important to assess the figure alongside the specific requirements of a role rather than viewing the national average as an expected salary. What influences thoracic surgeon compensation? Thoracic surgery involves highly specialised operative care, with compensation potentially influenced by the complexity and volume of surgical procedures undertaken. Individual thoracic surgeon compensation may also reflect experience, procedural workload, subspecialisation, call commitments, geographic market and employment model. A physician working within a large hospital system may have a different compensation structure from one employed by a specialist surgical group or another practice model. Productivity incentives, leadership responsibilities and other contractual components can further affect total compensation. These factors mean two thoracic surgeons can have significantly different compensation packages even when practising within the same specialty. What the latest figure means for thoracic surgeons For US thoracic surgeons, $749,707 provides a contemporary national reference point when reviewing existing compensation or assessing a prospective position. The figure can be particularly useful during contract discussions, but it should be considered alongside the complete requirements of the role. Surgical volume, call schedules, working hours, clinical responsibilities, location and incentive arrangements can all affect whether an individual compensation package is competitive. Non-financial considerations also matter. Factors such as clinical autonomy, operating capacity, support teams, workload and work-life balance can materially affect the attractiveness of a position even where headline compensation is similar. The latest Doximity data therefore provide thoracic surgeons with a valuable starting point for benchmarking compensation, rather than a single figure that should determine the value of an individual role. About the data The Doximity 2026 Physician Compensation Report provides compensation benchmarks across a wide range of US medical and surgical specialties. The specialty figures represent average compensation and should be treated as national benchmarks. An individual thoracic surgeon’s compensation may differ according to geography, experience, working arrangements, practice setting and other professional factors. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • US Neurosurgeon Compensation Reaches $829,161 After 10.7% Annual Increase

    Average neurosurgeon compensation increased to $829,161 in Doximity’s 2026 Physician Compensation Report, representing annual growth of 10.7%. Average annual compensation for US neurosurgeons reached $829,161, according to Doximity’s 2026 Physician Compensation Report. Neurosurgery compensation increased by 10.7%, making the latest data particularly relevant for neurosurgeons benchmarking their earnings against the wider US specialty workforce. Key findings Doximity reports average annual compensation of $829,161 for neurosurgeons in its latest analysis. This represents a substantial increase from the $749,140 average compensation reported for neurosurgery in Doximity’s 2025 report. The year-on-year movement equates to an increase of approximately $80,021, with Doximity reporting compensation growth of 10.7% for neurosurgery. For neurosurgeons assessing their own compensation, the figures provide a current national benchmark against which individual employment packages and practice earnings can be considered. Neurosurgeon compensation increases 10.7% The increase from $749,140 to $829,161 represents a significant movement in average compensation for the specialty. Importantly, this is not simply part of an equivalent increase across the entire physician workforce. Doximity reports that overall US physician compensation increased by 2% from 2024 to 2025, compared with the 10.7% increase recorded for neurosurgery. The latest figure therefore provides neurosurgeons with an important new reference point when evaluating compensation. However, the national average should not be interpreted as the salary that every neurosurgeon should expect to receive. Individual compensation can differ substantially according to factors including geography, experience, employment arrangement, workload and practice characteristics. What influences neurosurgeon compensation? Neurosurgery is a highly specialised surgical field involving the diagnosis and operative management of complex conditions affecting the brain, spine and nervous system. A neurosurgeon’s individual compensation can therefore reflect a range of factors, including surgical workload, case mix, subspecialty focus, call responsibilities, experience and employment structure. Practice setting can also be important when interpreting compensation data. Across physicians generally, Doximity found substantial differences in average compensation according to employment setting, with single-specialty groups, multi-specialty groups and hospitals among the settings associated with higher average physician compensation in its 2026 analysis. These broader findings provide context, but the $829,161 figure remains a national neurosurgery average rather than a guaranteed compensation level for a particular role or practice. What the latest figure means for neurosurgeons For US neurosurgeons, the new Doximity figure provides a useful contemporary benchmark when assessing compensation packages, considering a new position or evaluating how individual earnings compare with the national specialty average. The 10.7% annual increase is particularly notable. A neurosurgeon whose compensation has remained relatively static may therefore want to consider the latest market data alongside factors such as location, experience, workload, call commitments and employment model when evaluating their current position. At the same time, compensation should not be considered in isolation. Doximity’s wider 2026 research found that 76% of physicians surveyed were willing to accept lower pay in return for greater autonomy or work-life balance, illustrating the importance physicians place on factors beyond headline earnings. For neurosurgeons, the latest data ultimately establish a new specialty-specific benchmark: average annual compensation of $829,161, following growth of 10.7%. About the data Doximity’s 2026 Physician Compensation Report draws on nearly 23,000 compensation surveys completed by full-time US physicians during 2025, with its broader dataset incorporating more than 250,000 completed compensation surveys over seven years. Doximity states that respondents were full-time US physicians practising at least 40 hours per week. Individual compensation can vary according to geography, experience, working hours, practice setting and other factors, meaning the reported average should be treated as a national specialty benchmark rather than an expected salary for every neurosurgeon. Source Doximity. Physician Compensation Report 2026.https://www.doximity.com/reports/physician-compensation-report/2026#modal-close Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • TScan Therapeutics cuts workforce by 75% and pauses Phase 3 programme in strategic pivot

    TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours. The restructuring reflects a major strategic shift driven by capital constraints, with TScan prioritising development of its solid-tumour TCR-T programmes. The company is substantially reducing operating costs while concentrating its remaining resources on programmes it believes offer the strongest future development potential. Field Content Alert Type Industry Update Company TScan Therapeutics Update Type Strategic restructuring and workforce reduction Workforce Impact Approximately 75% workforce reduction Programme Impact Further enrolment in the Phase 3 ALLOHA-2 study paused Therapy Area(s) Oncology; solid tumours Technology or Modality TCR-T cell therapy; in vivo cell therapy What Happened TScan Therapeutics announced a strategic reorganisation involving a workforce reduction of approximately 75% and a pause in further enrolment in the Phase 3 ALLOHA-2 programme. Why It Matters The scale of the restructuring materially changes TScan's development strategy and reflects the financial pressures facing clinical-stage biotechnology companies. Strategic Focus Resources will be redirected towards in vivo cell therapy programmes for solid tumours. Supporting Context The company cited capital constraints as a key factor behind the decision to pause further ALLOHA-2 enrolment and reduce its cost base. Potential Impact The restructuring extends resources towards selected pipeline priorities but significantly reduces the company's near-term development footprint. Key Takeaway TScan is making a major strategic pivot towards in vivo solid-tumour cell therapy while cutting approximately three-quarters of its workforce. What to Watch Progress of TScan's in vivo solid-tumour programmes and any further changes to the ALLOHA-2 programme. Primary Source TScan Therapeutics Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • ADCAN Pharma and Pinnacle Life Science agree licensing and technology-transfer deal for 12 oncology products

    ADCAN Pharma and Pinnacle Life Science have entered into a licensing and technology-transfer partnership covering 12 oncology products and their planned local manufacture in the UAE. The agreement combines product licensing with staged technology transfer intended to build local manufacturing capability for critical oncology medicines. The partnership supports pharmaceutical localisation in the UAE while expanding ADCAN Pharma's oncology manufacturing portfolio. Field Content Alert Type Deal Companies ADCAN Pharma; Pinnacle Life Science Deal Type Licensing and technology-transfer agreement Assets 12 oncology products Therapy Area(s) Oncology Geography United Arab Emirates Deal Value Financial terms were not disclosed What Happened ADCAN Pharma and Pinnacle Life Science entered into an agreement covering the licensing of 12 oncology products and staged transfer of manufacturing technology to the UAE. Why It Matters The partnership expands local access to oncology products while supporting the development of domestic pharmaceutical manufacturing capacity. Strategic Rationale ADCAN gains access to a broader oncology portfolio and manufacturing know-how, while Pinnacle extends its products into the UAE market through a local partner. Potential Impact Successful technology transfer could increase local production of oncology medicines and reduce dependence on imported supply. Key Takeaway The agreement combines licensing of 12 oncology products with a structured programme to transfer manufacturing capability into the UAE. What to Watch Completion of the technology-transfer stages, regulatory approvals and commencement of local manufacture. Primary Source ADCAN Pharma Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Biocytogen licenses fully human VHH antibody to Qilu Pharmaceutical for neuroscience development

    Biocytogen has granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody from its RenNano platform for the development of neuroscience therapies. The agreement gives Qilu access to a Biocytogen antibody asset while allowing Biocytogen to continue licensing the platform and related assets to other partners. Financial terms and the specific therapeutic target were not disclosed, but the transaction adds another external development partnership around Biocytogen's antibody discovery technology. Field Content Alert Type Deal Companies Biocytogen; Qilu Pharmaceutical Deal Type Non-exclusive licensing agreement Asset or Company Fully human VHH antibody Platform RenNano Therapy Area(s) Neuroscience Technology or Modality Fully human VHH antibody Deal Value Financial terms were not disclosed What Happened Biocytogen granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody generated using its RenNano platform for use in neuroscience drug development. Why It Matters The transaction extends commercial use of Biocytogen's antibody discovery platform and gives Qilu access to a potentially differentiated antibody asset for neuroscience research. Supporting Context The specific therapeutic target and detailed development programme were not disclosed. Strategic Rationale The non-exclusive structure allows Biocytogen to monetise its platform while retaining the ability to pursue additional partnerships. Potential Impact The agreement may support development of new antibody-based treatments for neurological conditions if Qilu advances the programme successfully. Key Takeaway Biocytogen has licensed a RenNano-derived fully human VHH antibody to Qilu for neuroscience development under a non-exclusive agreement. What to Watch Disclosure of the target, development programme and any subsequent clinical progression. Primary Source Biocytogen / Qilu Pharmaceutical Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Qualcomm and ASUS launch pharmacy AI programme across southern Taiwan

    Qualcomm and ASUS have launched an on-premises AI assistant programme for community pharmacies across southern Taiwan. The initiative is designed to support medication safety, drug-interaction detection and pharmacy workflow efficiency using locally deployed artificial intelligence technology. The programme represents a practical healthcare deployment of generative AI infrastructure rather than a general technology demonstration. Field Content Alert Type Industry Update Companies Qualcomm; ASUS Update Type Healthcare AI deployment Sector Community pharmacy Technology On-premises AI assistant Use Cases Medication safety; drug-interaction detection; pharmacy workflow support Geography Southern Taiwan What Happened Qualcomm and ASUS launched an AI assistant programme for community pharmacies in southern Taiwan using on-premises computing infrastructure. Why It Matters The initiative demonstrates how generative AI tools are moving into frontline pharmacy workflows where privacy, local processing and medication-safety applications are particularly important. Supporting Context The system is intended to assist pharmacists with medication information, drug-interaction checks and operational workflows. Strategic Rationale On-premises deployment can support healthcare organisations that require greater control over sensitive data and system performance. Potential Impact Successful deployment could improve pharmacy efficiency and support safer medication management while providing a model for wider healthcare AI adoption. Key Takeaway Qualcomm and ASUS are deploying an on-premises AI assistant across community pharmacies in southern Taiwan to support medication safety and pharmacy operations. What to Watch Expansion of the programme, pharmacist adoption and evidence of improvements in workflow efficiency or medication safety. Primary Source ASUS Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page